Bulimia Nervosa Market

Market Overview:

The 7 major bulimia nervosa markets reached a value of US$ 369.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 606.1 Million by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034.

The bulimia nervosa market has been comprehensively analyzed in IMARC's new report titled "Bulimia Nervosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bulimia nervosa is an eating disorder characterized by recurrent binge eating episodes followed by compensatory behaviors such as self-induced vomiting, laxative use, or excessive exercise. Individuals who suffer from the condition often have a preoccupation with food and body image, experience feelings of guilt and shame, and may engage in secretive behavior related to their eating habits. Various other common symptoms include fluctuations in weight, dental problems, gastrointestinal issues, mood disturbances, etc. If left untreated, bulimia nervosa can have severe physical and mental health consequences, such as electrolyte imbalances, dehydration, malnutrition, increased risk of suicidal ideation, etc. The diagnosis of the ailment involves a comprehensive evaluation that takes into account the individual's medical history, physical indications, and psychological indications. Various medical exams and laboratory tests are ordered to assess the patient's overall health and rule out further conditions that could be causing the symptoms. Several psychological evaluations may include interviews, questionnaires, and other assessments to examine the individual's eating behaviors, body image, and mental health.

The increasing cases of abnormalities in brain chemistry or neurotransmitter systems, such as the serotonin system, are primarily driving the bulimia nervosa market. In addition to this, the rising incidences of several associated risk factors, including traumatic life events; psychological issues like poor body image, low self-esteem, and a tendency towards perfectionism; cultural pressure to be thin, etc., are also bolstering the market growth. Furthermore, the widespread adoption of antidepressant medications, such as selective serotonin reuptake inhibitors (SSRIs), for reducing the symptoms of depression and anxiety that often accompany the ailment is acting as another significant growth-inducing factor. Additionally, the increasing utilization of nutritional counseling to help individuals establish a healthy and balanced diet, as well as address any nutritional deficiencies that may have resulted from purging behaviors, is further augmenting the market growth. Moreover, the escalating demand for dialectical behavior therapy (DBT) on account of its several associated benefits, such as improved interpersonal relationships and reduced impulsive behaviors, is also creating a positive outlook for the market. Apart from this, the emerging popularity of mindfulness-based interventions, since they aid in lowering stress, improving emotional regulation, and promoting self-compassion and acceptance, is expected to drive the bulimia nervosa market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the bulimia nervosa market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bulimia nervosa and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bulimia nervosa market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the bulimia nervosa market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the bulimia nervosa market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current bulimia nervosa marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the bulimia nervosa market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the bulimia nervosa market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the bulimia nervosa market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of bulimia nervosa across the seven major markets?
• What is the number of prevalent cases (2018-2034) of bulimia nervosa by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of bulimia nervosa by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of bulimia nervosa by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with bulimia nervosa across the seven major markets?
• What is the size of the bulimia nervosa patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of bulimia nervosa?
• What will be the growth rate of patients across the seven major markets?
   

Bulimia Nervosa: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for bulimia nervosa drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bulimia nervosa market?
• What are the key regulatory events related to the bulimia nervosa market?
• What is the structure of clinical trial landscape by status related to the bulimia nervosa market?
• What is the structure of clinical trial landscape by phase related to the bulimia nervosa market?
• What is the structure of clinical trial landscape by route of administration related to the bulimia nervosa market?